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Aim: To determine construct validity and reliability indicators of the Cochrane risk of bias 
(RoB) tool in the context of randomized clinical trials (RCTs) for autism spectrum disorder 
(ASD).
Methods: Confirmatory factor analysis was used to evaluate a unidimensional model 
consisting of 9 RoB categorical indicators evaluated across 94 RCTs addressing inter-
ventions for ASD.
Results: Only five of the nine original RoB items returned good fit indices and so were 
retained in the analysis. Only one of this five had very high factor loadings. The remain-
ing four indicators had more measurement error than common variance with the RoB 
latent factor. Together, the five indicators showed poor reliability (ω = 0.687; 95% CI: 
0.613–0.761).
Conclusion: Although the Cochrane model of RoB for ASD exhibited good fit indices, 
the majorities of the items have more residual variance than common variance and, 
therefore, did not adequately capture the RoB in ASD intervention trials.
Keywords: autism spectrum disorder, risk of bias, confirmatory factor analysis, meta-analysis, randomized 
controlled trials
INtRodUCtIoN
Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by impairments 
in reciprocal social interaction and stereotyped and repetitive behaviors. Several empirically sup-
ported behavioral interventions have been shown to improve core features of ASD, including 
social communication [e.g., Ref. (1–4)]. Psychopharmacological treatments have been shown to 
decrease secondary symptoms, such as aggression, irritability, and hyperactivity [e.g., Ref. (5)]. 
As diagnoses are being made at younger ages and as the prevalence of ASD increases, research has 
increasingly focused on the development of cost-effective, community viable interventions. This 
is especially relevant as resources are limited and as clinicians aim to effectively and efficiently 
guide families in making treatment decisions. Information on what treatments are truly effec-
tive for which individuals is invaluable. Randomized clinical trials (RCTs) are considered the 
“gold standard” for determining intervention effectiveness and efficacy. Hundreds of RCTs are 
published every year, making it nearly impossible for practicing professionals to keep abreast of 
the effectiveness literature. In addition, RCT results may often contradict one another, and though 
some studies are well designed, others may be poorly designed and executed.
tABle 1 | Nine items of the “risk of bias” (RoB) factor.
RoB items Code
Random sequence generation (sequence bias) RSG
Allocation concealment (selection bias) AC
Incomplete outcome data (attrition bias) IOD
Blinding of participants and personnel (performance bias) BPP
Blind of outcome assessment (detection bias) BOA
Selective reporting (reporting bias) SR
Other bias OB
Baseline measurements BM
Protection against contamination PAC
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One way to aggregate these results is via systematic reviews 
and meta-analyses, in which different strategies have been 
employed to identify and evaluate the risk of bias (RoB). The 
most widely used strategy is the Cochrane Risk of Bias Tool, 
developed by the Cochrane Collaboration (6). To assess RoB in 
RCTs, they recommend the following indicators/items (called 
domains by the authors): random sequence generation (RSG), 
allocation concealment, participant and personnel blinding, 
outcome assessment blinding, incomplete outcome data, selec-
tive reporting, and other sources of bias, including important 
circumstance-specific concerns about bias that are not addressed 
in the other domains.
According to the Cochrane Risk of Bias Tool (6), each indica-
tor should be evaluated by the systematic review’s authors on a 
scale with three ordinal categories of response: low risk, unclear 
risk, or high RoB. Issues regarding the Cochrane tool have 
emerged due to concerns of reliability. For example, some items 
lack agreement among authors (45% of the judgments of risk 
differed), especially for particular items (e.g., blinding, selective 
reporting). As such, there are large discrepancies in how RoB is 
being evaluated (7).
The first study in the literature evaluating the construct 
validity of RoB was recently conducted by Rodrigues-Tartari 
et al. (8). In a review of RCTs evaluating methylphenidate for 
ADHD, the authors found that the Cochrane Risk of Bias Tool 
has poor evidence of construct validity and was an unreliable 
instrument (ω = 0.642) for the RCTs under review. The authors 
concluded, however, that such a negative finding might be a 
context-specific result of sampling 184 primary RCTs.
Due to the prevalence and increased focus of RCTs and 
systematic reviews covering different types of interventions for 
ASD, it is necessary to critically evaluate the way that effective-
ness and efficacy have been evaluated. Here, we aim to investigate 
the construct validity of the Cochrane Risk of Bias Tool in the 
context of RCTs for ASD.
Method
This research was approved by the Ethics Committee of Research 
of the Federal University of Sao Paulo (UNIFESP).
Meta-analyses specifically focusing on interventions for ASD 
were selected. Interventions with other types of developmental 
disorders were excluded. Ten intervention systematic Cochrane 
meta-analyses were considered in this study, consisting of 94 
original RCTs. The 10 meta-analyses included were Fletcher-
Watson, et  al. (9), Geretsegger et  al. (10), Hurwitz et  al. (11), 
James et al. (12), Oono et al. (13), Reichow et al. (14), Reichow 
et  al. (15), Sinha et  al. (16), Williams et  al. (17), and Williams 
et al. (18). The total number of studies within each meta-analysis 
varied from 1 to 21 (mean of 9 per study, totaling 94 primary 
RCTs). The meta-analyses were conducted from 2010 to 2015. 
The studies within the meta-analyses were conducted from 1989 
to 2013.
For each included RCT, data extractors (i.e., authors of the 
systematic reviews) independently evaluated all RoB domains 
(the items). As such, for this analysis, data were provided by 
the RoB summary in each included study and not determined 
by the present study’s authors. Each bias domain was detailed 
in the meta-analysis using an ordinal rating scale consisting of 
the following three categories: low RoB, uncertain RoB, or high 
RoB, according to the Cochrane guidelines. Data on the level of 
agreement between the data extractors (authors of the systematic 
reviews) across the items are not presented because any disagree-
ments were resolved by discussion and negotiation with a third 
author, as per best practices. Together with the seven commonly 
used RoB, based on research by Reichow et al. (15), additional 
indicators were occasionally used—“Baseline Measurements 
(BM)” and “Protection against contamination (PAC).”
Though the systematic reviews cited above commonly use 
only the original seven items of bias (excluding BM and PAC), 
some used the additional indicators (for a total of 9). For these 
analyses, we consider all reported items; thus, if a given system-
atic review did not have the additional two items (BM and PAC), 
they were considered as missing values. Underlying these nine 
ordinal items an a priori latent attribute called RoB was specified. 
Table  1 depicts the name and code for each risk of bias item 
included in the analysis.
statistical Analysis
Confirmatory factor analysis (CFA) was used to evaluate 
(a) the goodness of fit of the measurement model proposed by 
the Cochrane Collaboration and (b) the strength of the cor-
relation between the items and the overall RoB factor. In this 
way, the factor loading is a correlation between the observed 
categorical item and the latent measure (RoB) where the higher 
the correlation, the lower the items’ residual variance. As such, 
the lower the residual variance, the higher the reliability index 
of each RoB’s indicator. CFA is commonly applied to provide 
construct validity to tests, scales, questionnaires, and batteries. 
Typically, these tools assess human attributes such as psycho-
pathology (i.e., depression, anxiety), skills (academic skills), 
health (well-being, happiness), and other latent measures (i.e., 
theoretical constructs underlying the test which are not directly 
observed). Similarly, though less frequently, these techniques 
are applied to measure non-human attributes in the healthcare 
field. To the best of our knowledge, there is only one study 
using CFA to provide construct validity of RoB (8). This study 
is thus innovative in the application of CFA to RoB in the field 
of ASD.
The unidimensional model (i.e., a model in which all the 
RoB items load onto a single latent attribute) was chosen for 
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two primary reasons. First, a reduced number of dimensions 
may leave the model with a parsimonious solution. This would 
create the simplest model with the least number of assumptions 
and variables but with greatest explanatory power in terms of 
interpretability of the measurement model (19). Second, there 
are no clear descriptions by Cochrane Collaboration about how 
the indicators should be grouped to form subfactors to generate a 
multidimensional solution.
Several fit indices were used to evaluate the RoB model 
including: chi-square (χ2), confirmatory fit indices (CFI), the 
Tucker–Lewis index (TLI), and root mean square error approxi-
mation (RMSEA). The following cutoff criteria were used to 
determine a good model of fit: a non-statistically significant 
chi-square p-value (>0.05), a RMSEA near or less than 0.06, and 
CFI and TLI near or greater than 0.95 (20). The weighted least 
square using a diagonal weight matrix with SEs and mean- and 
variance-adjusted (WLSMV) estimator was used (21) because the 
observed indicators (i.e., RoB items) are ordinal [i.e., a categorical 
item with three possible answers (low, unclear, and high RoB)]. 
Due to the complex sampling structure (i.e., 94 clinical trials 
within 10 systematic reviews), SEs were computed by a sandwich 
estimator and a chi-square test of the model fit which took into 
account the non-independence of observations. For more detail 
and discussion about such implementation, see Ref. (22, 23). The 
adopted statistical significance level was 0.05. All analyses were 
run using Mplus 8.0 (24).
As the precision of the set of items used to measure the con-
tinuous latent attribute RoB was not constant across the whole 
RoB latent trait, the total information curves (TIC) were used 
to verify where in the RoB latent trait there is more precision 
(i.e., amount of information). The utility of TIC is to inspect 
where, across the RoB latent trait, we can observe better preci-
sion (i.e., the amount of information captured) in specific RCTs. 
On the X-axis, the range of the RoB latent trait is presented in 
z-scores with a range from −3 to +3 and a mean of 0, where −3 
is the highest RoB (lowest in terms of study quality) and +3 is 
the lowest RoB (highest in terms of study quality). On the Y-axis 
is the amount of information, which can range from 0 to infinity 
and thus has no maximum.
To evaluate Cochrane’s RoB reliability, we adopted the 
omega total (ω) (25, 26) because omega is an alternative to 
Cronbach’s alpha reliability coefficient. Omega total is used 
when the item set does not adhere to tau equivalence (i.e., the 
items does not contribute equally to the total scale score, not 
having, consequently, the same “weight” on how they are mea-
suring RoB). Moreover, omega is used when the RoB items are 
not on a continuous scale, are not normally distributed, and the 
errors of the items (i.e., residual variance) may covary (i.e., the 
errors are correlated), as such, with the meta-analyses included 
in this study. Although Cronbach’s alpha presents this unre-
alistic assumptions (27, 28), to use both, unidimensionality is 
a requisite (29).
Omega total (ω) is a composite reliability index for congeneric 
scales (tests where the set of items are loaded onto a single factor) 
and is closely related to Cronbach’s alpha. Omega total assesses 
reliability via a ratio of the variability explained by items to the 
total variance of the entire scale (30, 31). This test information 
function arises from item response theory and can be considered 
a modern and powerful reliability estimation procedure when 
investigating the internal consistency of measurements (32). 
Also, according to Dunn et  al. (29) “as the congeneric model 
allows item variances to vary (i.e., they are not assumed to be 
constant) it will not result in the lower bound estimations of reli-
ability characteristic of alpha.”
The main advantages of omega over alpha can be summari-
zed as follows: (1) Omega makes fewer and more realistic 
assumptions than alpha, (2) problems associated with inflation 
and attenuation of internal consistency estimation are far 
less likely, (3) employing “omega if item deleted” in a sample 
is more likely to reflect the true population estimates of reli-
ability through the removal of a certain scale item, and (4) the 
calculation of omega alongside a confidence interval reflects 
much closer the variability in the estimation process, providing 
a more accurate degree of confidence in the consistency of scale 
administration (29).
The reliability measures are nearly always reported as point 
estimates, and there is no clear cutoff point. Bland and Altman (33) 
suggest that “a Cronbach’s alpha reliability coefficient greater than 
0.7 is quite sufficient in many cases.” Kottner et al. (34) indicate 
that “values of 0.60, 0.70, or 0.80 are often used as the minimum 
standards for reliability coefficients in research, however, when 
applied in clinical practice, if individual and important decisions 
are made on the basis of reliability estimates, values should be at 
least 0.90 or 0.95.” As omega total (ω) has a similar interpretation 
to alpha, Rodriguez et al. (35) state that “a value higher than 0.8 
indicates a sufficient relationship between the latent variable and 
item scores.”
Intrinsically linked with the reporting of alpha and omega as 
a point estimate, is the use of a cutoff heuristic, thought to reflect 
the crucial stage at which a scale possesses good or poor internal 
consistency (29). The heuristic in reliability reporting is based 
on work by Nunnally (36) who states that “what a satisfactory 
level of reliability is depends on how a measure is being used. 
In the early stages of research […] one saves time and energy 
by working with instruments that have only modest reliability, 
for which purpose reliabilities of 0.70 or higher will suffice […]. 
In contrast to the standards in basic research, in many applied 
settings a reliability of 0.80 is not nearly high enough. In basic 
research, the concern is with the size of correlations and with the 
differences in means for different experimental treatments, for 
which purposes a reliability of 0.80 for the different measures is 
adequate. In many applied problems, a great deal hinges on the 
exact score made by a person on a test […]. In such instances it 
is frightening to think that any measurement error is permitted. 
[…]. In those applied settings where important decisions are 
made with respect to specific test scores, a reliability of 0.90 
is the minimum that should be tolerated, and a reliability of 
0.95 should be considered the desirable standard” [(36), pp. 
245–246].
ResUlts
Initially, a 1-factor solution with nine items was tested, but the 
model was not admissible because the PAC item contained 
tABle 2 | R2 and residual variances (measurement error) by item.
Items R2 Residual variance
BPP 0.384 0.616
BOA 0.310 0.690
IOD 0.023 0.977
SR 0.191 0.809
OB 0.828 0.172
BPP, blinding of participants and personnel (performance bias); BOA, blinding of 
outcome assessment (detection bias); IOD, incomplete outcome data (attrition bias); 
SR, selective reporting (reporting bias); OB, other bias.
FIgURe 1 | Risk of bias model. rob, risk of bias; bpp, blinding of participants 
and personnel (performance bias); boa, blind of outcome assessment 
(detection bias); iod, imcomplete outcome data (attrition bias); sr, selective 
reporting (reporting bias); ob, other bias. Note: numbers on left side of 
parentheses are the factor loadings and within the parentheses their 
respective SEs.
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less than two categories (i.e., only the high RoB category was 
endorsed). Excluding PAC and rerunning the model with eight 
items returned a statistical problem because the minimum 
covariance coverage was not fulfilled. This error was due to 
problems in estimating correlation between two pairs of items: 
(a) BM and AC and (b) BM and OB. To keep the majority of the 
originally proposed items in the model, only the item, BM, was 
excluded. Rerunning the model with seven indicators resulted 
in a new inadmissible solution involving the AC item, and so 
AC was excluded. Thus, three items were excluded from the 
original set due to statistical problems related to the model’s 
convergence and admissibility. The model becomes estimable 
with 1-factor and 6 items, however, without appropriate fit 
indices [χ2(9) = 11.325, p = 0.254; CFI = 0.918; TLI = 0.864, 
RMSEA  =  0.052 (90% confidence interval  =  0.000–0.134, 
Cfit = 0.424); WRMR = 0.689], and with TLI being below the 
suggested cutoff.
The correlation between the RSG and the RoB attribute 
was not relevant (i.e., it was close to 0) and the factor loading 
was statistically insignificant (λ = 0.043, p = 0.692), indicating 
that RSG is poorly related to the RoB factor. Thus, RSG was 
excluded from the model. By removing the RSG indicator, the 
model with 1-factor and 5 items presented excellent fit indices, 
as follows: χ2(5) = 5.093, p = 0.4047; CFI = 0.997; TLI = 0.994, 
RMSEA  =  0.014 (90% confidence interval  =  0.000–0.145, 
Cfit = 0.536); WRMR = 0.689.
Figure 1 shows the diagram with the RoB model with excellent 
fit, made up of five indicators. As can be seen in Figure 1, the 
best item (the item most related to the RoB factor) is the Other 
Bias (λ = 0.910, p < 0.001). Negative factor loadings indicate that 
the items were inversely correlated to the RoB factor. The first 
two indictors, blinding of participants and personnel and blind 
of outcome assessment had moderate and statistically significant 
correlations with the RoB factor, indicating methodological 
strengths of the RCTs.
Therefore, the final model has excellent fit indices and factor 
loadings that vary from 0.153 to 0.910, with “other bias” exhibit-
ing the highest factor loading. However, the amount of explained 
variance (i.e., R2) of the majority items in relation to the latent 
attribute (RoB) is small, as shown in Table 2.
Figure 2 shows the total curve of information for the RoB 
trait. It shows that the five items provide more precise informa-
tion (i.e., higher amount of precision) in the lowest to middle 
spectrum of latent trait (i.e., z-score around −1.5 and −0.5). 
This means that the RoB latent trait was able to capture a greater 
amount of information in the RCTs with a low to medium 
amount RoB (the negative part of the spectrum). This means 
that the latent trait (RoB) captured by the RoB factor is more 
suitable for evaluating ASD intervention trials with a low RoB 
(it means lowest in terms of study quality).
Finally, the omega for the five indicators was 0.687 (95% CI: 
0.613–0.761).
dIsCUssIoN
Based on CFA, we found that the five risks of bias items in the 
context of RCTs for ASD have construct validity returning 
excellent fit indices under a unidimensional model. The initial 
model with nine and seven items was not adequate to assess 
RoB for ASD intervention trials. For this study, only a unidi-
mensional model was tested because there is no clear theory 
from the original descriptions of RoB tools provided by the 
Cochrane Collaboration (6) to support alternative configurations 
(e.g., seven indicators grouped into two factors).
It is important to note that, although the model fit indices 
showed strong values, the majority of the items had a greater 
amount of measurement error/residual variance than com-
mon variance, which raises an important issue of how reliably 
the items capture a unidimensional RoB factor as proposed by 
Cochrane. CFA includes the modeling of the measurement error 
associated with each indicator (latent variables regressed on the 
items with ε inside the ovals), and measurement error is what 
establishes the reliability of each item (37).
High Risk Low Risk 
Low risk of bias High risk of bias 
FIgURe 2 | Total information curve of risk of bias factor.
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In terms of reliability, only one item, “other bias,” had high 
factor loading, low measurement error, and low residual vari-
ance. Four items had high measurement error and high residual 
variance and average factor loading. The item “incomplete out-
come data” had very low factor loading and high measurement 
error and residual variance. This high degree of measurement 
error/residual variance across the majority of the items resulted 
in an omega total of 0.687 for the scale, indicating that the 
test is essentially 1% point below what is described above by 
Nunnally (36). Even with an upper confidence interval that is 
within what can be considered “acceptable,” the test indicates 
a less than moderate relationship between the latent variable 
and item scores and consequently a “low” reliability of test 
score.
Still, the item “incomplete outcome data” exhibited factor 
loadings below 0.4 and the item “selective report” was close to 
0.4. According to Nunnally (38), “it is easy to overinterpret 
the meaning of small factor loadings, e.g., those below 0.40.” 
Therefore, among those remaining five items, only three had 
factor loadings higher than this cutoff. However, when we 
focused on the residual variance, the “other bias” item was the 
only item that exhibited more reliable variance. Consequently, 
this is reflected in the omega as a generally reliable measure of 
the set of items.
According to Brown (19), pp. 135–136, “… Even if a model is 
very successful at reproducing the observed relationships in the 
input matrix, this does not ensure that the latent variables are 
substantively interrelated or account for meaningful variance in 
the indicators. Thus, it is just as important to consider the size of 
the model’s parameter estimates as it is to consider the model’s 
goodness of fit in determining the acceptability of the solution.” 
This means that, for the model presented in this study, the latent 
factor is not substantively accounting for meaningful variance 
in the majority of the proposed RoB items.
In terms of precision, the set of items most reliable to 
measure RCT studies are the ones that have higher RoB 
(shown in Figure 2 by the studies which fall on the left side 
of the graph). These studies are of lower quality as they have 
a higher RoB.
Finally, although the items from our model show better 
indices, the results of this study were consistent with those of 
Rodrigues-Tartari et al. (8), who found that the RoB model for 
RCTs for trials of methylphenidate for children and adolescents 
with ADHD have poor reliability. Therefore, the Cochrane RoB 
tool is insufficient when applied to ASD clinical trials. As such, 
better indicators to capture RoB among intervention for ASD are 
needed.
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